CFO of HIMS & HERS Buys 14,000 Shares at $5.01 Despite 50% Stock Loss, Insider Confidence Signals Long‑Term Faith in Telehealth Growth

Insider Activity Spotlight: HIMS & HERS Health CFO Buys 14 k Shares

On September 22, 2026, Chief Financial Officer Okupe Oluyemi executed a Rule 10b5‑1‑planned purchase of 14,000 Class A shares at $5.01 each. The buy‑side trade comes after a 29,277‑share sale at $29.95 earlier that day, leaving his holdings at 265,804 shares. The transaction is part of a broader pattern of disciplined trading under the CFO’s 10b5‑1 plan, which has seen him buy and sell in equal measure over the past months.

What the Mix of Buying and Selling Signals

Oluyemi’s recent trades reveal a classic “round‑trip” strategy: buying low, selling high, and vice versa, all scheduled under the same rule‑based plan. The July‑through‑August activity shows roughly 70 % of his trades are sales, while about 30 % are purchases, keeping his net exposure stable. The latest purchase at $5.01 is a fraction of the prevailing market price (~$28.39), suggesting he is hedging against potential downside or simply locking in a long‑term stake at a discount. For investors, this indicates the CFO trusts the company’s long‑term prospects enough to hold a sizable position, yet remains flexible to capitalize on short‑term opportunities.

Investor Takeaway: Confidence Amid Volatility

HIMS & HERS is trading near a 52‑week low of $13.74, with a year‑to‑date loss of over 50 %. Despite the weak fundamentals—negative P/E and a steep monthly decline—Oluyemi’s buying activity underscores a belief that the company’s telehealth platform and recent IT‑services contract will drive future revenue. For shareholders, his disciplined plan can be a signal of institutional confidence, especially when juxtaposed with the broader insider sell‑pressure from other executives in September.

Oluyemi: A Track Record of Tactical Trading

Since early 2026, Oluyemi has executed more than 30 separate 10b5‑1 trades, totaling roughly 1.4 million shares bought and sold. His portfolio swings between 260,000 and 300,000 shares, reflecting a cautious long‑term view. He has also traded restricted stock units and stock options, but the bulk of his activity remains in Class A common stock. Historically, his trade sizes are modest relative to total shares outstanding (~70 M), suggesting he is not a dominant shareholder but a committed participant in the company’s growth trajectory.

Market Context: A Bullish Signal?

The trade’s timing—just as the stock edges above $28—coincides with a spike in social‑media buzz (154 %) and a positive sentiment (+51). While the buzz may be reactionary, the CFO’s purchase amid heightened chatter could reinforce investor confidence. For market watchers, the combination of a well‑structured 10b5‑1 plan and a favorable public sentiment profile provides a nuanced, albeit cautious, narrative: insiders believe in HIMS & HERS, even as the stock faces significant downside risk.

In short, Okupe Oluyemi’s recent buy, set against a backdrop of strategic selling and a bullish social‑media environment, hints at a long‑term faith in the company’s telehealth and IT‑services expansion, while reminding investors of the inherent volatility still looming in the stock’s performance.